CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenues:
Patient services	$ 24,705	$ 23,663
Research services	4,872	415
Product	2,841	2,967
Total revenues	32,418	27,045
Cost of revenues:
Patient services	8,764	9,471
Research services	2,738	155
Product	1,371	1,809
Total cost of revenues	12,873	11,435
Gross profit	19,545	15,610
Operating expenses:
General and administrative	9,528	8,673
Sales and marketing	6,762	6,152
Bad debt expense	2,467	2,911
Research and development	1,620	1,185
Integration, restructuring and other charges	1,202	270
Total expenses	21,579	19,191
Loss from operations	(2,034)	(3,581)
Other income (expense):
Interest income		169
Interest expense	(27)
Other expense, net	(26)	(122)
Total other income	(53)	47
Loss before income taxes	(2,087)	(3,534)
Net loss	(2,087)	(3,534)
Net loss per common share:
Basic and diluted (in dollars per share)	$ (0.08)	$ (0.14)
Weighted average number of common shares outstanding:
Basic and diluted (in shares)	25,190,566	24,604,812
Unrealized gains/(losses) on securities:
Unrealized holding gains/(losses) arising during the period		(8)
Comprehensive Loss	$ (2,087)	$ (3,542)